Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness of Adalimumab biosimilar in Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis

Next Previous
Trial Profile

Effectiveness of Adalimumab biosimilar in Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2018

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use

    • Most Recent Events

    • 27 Nov 2018 New trial record
    • 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top